News & Updates
Lung Cancer Canada has added two new social media profiles.
Follow us on LinkedIn and Instagram!
The 2016 Cancer System Performance Report is the seventh report of indicators measuring cancer system performance across Canada.
System Performance Reports provide a pan-Canadian cross-section of key performance indicators that allow for the interpretation of patterns and trends to inform opportunities for overall system improvements.
More good news for lung cancer patients: Health Canada approves Tagrisso for treatment of NSCLC
Lung Cancer Canada would like to welcome Dr Paul Wheatley-Price as our new President. Dr Wheatley-Price was voted in at the Annual General Meeting held on June 15, 2016.
The Lung Cancer Canada Summer Studentship Grant Program provides support for highly qualified applicants in all areas of lung cancer health research at all post-secondary stages to add to their experience by engaging in health research in Canada. A number of $5,000 (CDN) grants are available as a one-time funding opportunity.
Please contact Lung Cancer Canada ([email protected]) if you are a patient or caregiver of a patient on Keytruda. Your experience with this treatment is a crucial part of the decision process!
Tenacious Dr. Terry-Nan Tannenbaum, renowned public health physician, fought super-bugs, SARS, tuberculosis and HIV in others for decades until her fight became personal when she was diagnosed with terminal lung cancer.
Dr. Rosalyn Juergens' interview with Pauline Chan at CTV News on the promising results from the drug Opdivo (Nivolomab).
pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.
This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer.
Your experience with cancer care in Ontario depends greatly on the type of cancer you have, the kind of treatment you are prescribed, your age and family income – all of which can make or break the timeliness and quality of care you receive. Ontario’s two-tiered cancer drug system includes widely different drug reimbursement models and variable safety standards and support for patients who take their cancer medications at home versus in a hospital or cancer clinic.